Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    2,782

Stocks News & Analysis

stocks

Undervalued ASX share with plan to mitigate tariff risk

Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks

Earnings up but shares overvalued for ASX gold miner

Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,351.904.90-0.05%
CAC 408,239.1813.550.16%
DAX 4024,308.7868.890.28%
Dow JONES (US)47,544.59337.470.71%
FTSE 1009,653.828.200.09%
HKSE26,433.70273.551.05%
NASDAQ23,637.46432.591.86%
Nikkei 22550,512.321,212.672.46%
NZX 50 Index13,334.5357.06-0.43%
S&P 5006,875.1683.471.23%
S&P/ASX 2009,055.602.20-0.02%
SSE Composite Index3,996.9446.631.18%

Market Movers